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Studies indicate that <50% of polymyalgia rheumatica (PMR) patients receive bone protective therapy (BPT) 
forglucocorticoid-induced osteoporosis (GIOP) prevention. We sought to determine if PMR patients are protected 
fromGIOP by examining bone densitometry (DXA) scan results, BPT use, and adherence to guidelines.  
Methods 
PMR patients treated with glucocorticoids who underwent a DXA scan at Cork University Hospital from 01/01/2016 
to27/10/2017 were included. Patient data were obtained from chart review.    
 
Results 
Out of 153 patients, 73 (47.7%) were taking BPT and 42 (27.5%) were not. At the most recent DXA scan, 42 (27.5%) 
had normal BMD, 84 (54.9%) were osteopaenic, and 27 (17.6%) were osteoporotic. In 91 individuals who 




Despite recommendations, many patients are not prescribed BPT. The results suggest that PMR patients in Cork 
arenot optimally protected from GIOP. 




Polymyalgia Rheumatica (PMR) is the second most common rheumatic disease in adults primarily affecting females 
over 50 years old1. Its peak incidence in the United Kingdom is approximately 2.3 per 1,000 patient-years between the 
ages of 70 and 792. Majority of PMR cases are managed in the primary care setting but the care of PMR patients varies 
widely3. 
 
Glucocorticoids (GCs) are the standard of care, which typically provide quick and effective improvement in symptoms. 
However, the relapsing and remitting nature of this illness, often requires GC treatment for ≥2 years3. PMR is one of 
the most common indications for long-term GC therapy (>3 months) in the community, accounting for 22% of GC 
prescriptions in the UK4. Most patients are started on a dose of 12.5-25 mg per day of prednisolone/prednisone-
equivalent.  If symptoms do not resolve in a few days, the dosage may be increased3. 
 
GC adverse effects are common in PMR, occurring in approximately 50% of patients, and present a further challenge 
to management5,6. Osteoporosis, with resultant fractures, is one of the most morbid of these complications, especially 
considering given PMR patients are typically post-menopausal women already vulnerable to BMD loss. Just 3 months 
of GC therapy has shown to cause rapid decline in BMD loss detectable by bone densitometry (dual-energy X-ray 
absorptiometry [DXA]) scan7. For this reason, the Irish Osteoporosis Society recommend that patients expecting to 
take at least 5 mg of prednisolone per day (or equivalent) for at least 3 months, should undergo a DXA scan at the 
initiation of treatment and every 2 years afterward to trend bone density measurements8. 
 
The American College of Rheumatology (ACR) have developed the guidelines and recommendations regarding 
preventative measures for GC-induced osteoporosis (GIOP)8.  Calcium plus vitamin D supplementation is indicated for 
all patients beginning GC therapy but bisphosphonates are recommended for the vast majority of patients initiating 
long-term GCs, which have shown to maintain BMD9,10.  These guidelines are adhered to inconsistently in the literature. 
One study reported less than 1/3 of patients received calcium and vitamin D supplementation10. Another study 
investigating prevention of GIOP in PMR patients specifically, reported that less than 30% of patients received 
bisphosphonates upon initiation of GC therapy. Analyzing individual patient cases revealed that 92% of patients should 
have received osteoporosis prophylaxis if the ACR guidelines were adhered to11.  
 
The evidence presented above indicates that PMR patients on long-term GCs may not be sufficiently protected from 
GIOP. It is uncertain whether PMR patients initiating GC therapy are receiving bone protective therapies (BPTs), such 
as calcium plus vitamin D, bisphosphonates, or teriparatide. 
 
The objective of this study was to determine whether or not PMR patients are protected against GIOP. This was 
explored by determining the prevalence of osteoporosis and osteopaenia in this patient group, correlating T-scores of 





This study protocol was approved in December 2016 by the University College Cork Clinical Research Ethics Committee 
of Cork Teaching Hospitals. 
 
Participants in this study were patients with a documented diagnosis of PMR and a history of chronic GC use. Patients 
were included in the analyses if they underwent a DXA scan over a 22-month time frame (01/01/2016 to 27/10/2017) 
at the Cork University Hospital (CUH) Bone Densitometry (DXA) Department. Patients who had no documented history 
of GC use were excluded from the study.  
 
A separate subanalysis was conducted for patients who underwent ≥2 DXA scans by 27/10/2017. The difference 
between the last and first T-scores were calculated to determine whether or not BMD decreased, increased, or stayed 
the same.  
 
Patient information was collected from the DXA Department patient database in CUH, including: age, gender, height, 
weight, smoking status, previous fractures, other medical conditions, and medications, including BPT such as calcium, 
vitamin D, bisphosphonates, denosumab, parathyroid hormone, and strontium. DXA reports within the database were 
also obtained to determine the T-scores at each scan.   
 
Statistical Package for Social Sciences (SPSS) was used to analyse the data. Simple descriptive statistics were used to 
analyse baseline demographics of patients, in addition to BMD category (using T-scores patients were determined to 
be normal BMD, osteoporotic, or osteopaenic) and BPT use (none, calcium or vitamin D, or guideline-adherent). The 
Pearson’s χ2 test was used for the binomial categorical variables, whether or not the patient was taking BPT, presence 
of normal or low BMD (using most recent T-scores), and evidence of radiologic BMD loss over time (either decreased 
or not decreased). The associated p-values are reported. An independent t-test compared mean T-scores obtained 










Table 1 outlines the demographics of PMR patient identified for in this study. From 01/01/2016 to 27/10/2017, there 
were 182 PMR patients who underwent DXA scans, of whom 153 had a documented history of GC use at the time of 
their scan and were included in this analysis. 
 
Table 1: Polymyalgia Rheumatica Patient Demographics 
 
 N (%) 
Total 153 (100) 
Gender  
Female 105 (68.6) 
Male 48 (31.4) 
Age  
<50 1 (0.7) 
51-60 16 (10.5) 
61-70 45 (29.4) 
71-80 68 (44.4) 
>80 23 (15.0) 
BMI  
Underweight (<19) 2 (1.3) 
Normal (19-25) 36 (23.5) 
Overweight (26-30) 68 (44.4) 
Obese (>30) 47 (30.7) 
Smoking Status  
Current/Previous Smoker 33 (21.6) 
Non-Smoker 120 (78.4) 
History of Adult Fracture  
Yes 55 (35.9) 
No 98 (64.1) 
Other Medical Condition*  
Yes 87 (56.9) 







Figure 1 shows the prevalence of osteoporosis and osteopaenia within this group. On analyzing the most recent T-
scores of individual patients, 42 (27.5%) had normal BMD (T-score > -1.0), 84 (54.9%) had osteopaenia (T score 
between -1.0 and -2.5), and 27 (17.6%) had osteoporosis (T-score ≤ -2.5).  
 
 
Figure 1: Prevalence of Osteopaenic and Osteoporotic Patients 
 
*Other medical conditions include: diabetes, chronic kidney disease, 
hypertension, heart failure, hyperlipidemia, coronary artery disease, hyper- or 
hypothyroid, history of cancer diagnosis, osteoarthritis, rheumatoid arthritis, 





Adherence to Guidelines 
 
Out of 153 PMR patients, 111 (72.5%) were on some sort of bone protective therapy and of these, 38 were taking 
monotherapy calcium or vitamin D. Therefore, in total, 80 patients (52.3%) are not receiving guideline-adherent BPT 
and 73 (47.7%) are receiving BPT per current guidelines (Figure 2). Of these 73 patients, 44 (28.8%) patients were 
taking bisphosphonates, 8 (5.2%) patients were on denosumab, and 2 (1.3%) were taking Strontium.  
 
 




Correlations Between Bone Protective Therapies and Bone Mineral Density Loss 
 
Of the 73 patients receiving BPT consistent with current guidelines, the mean T-score was -1.76 (SD=1.11). Of the 80 
patients not receiving guideline-adherent BPT, the mean T-score was -1.41 (SD=0.97). There is a statistically significant 
difference between these (p=0.04, 95% CI -0.7 to -0.01) indicating that patients on BPT are significantly more likely to 
have a lower T-score. Of note, 15 (9.9%) patients had normal BMD and 58 (38.2%) were classified as osteopaenic or 
osteoporotic on their most recent DXA scan. Of the patients who were not receiving proper BPT, 27 (17.6%) were 
classified as having normal BMD, and 53 (34.6%) were classified as osteopaenic or osteoporotic. However, these 
findings were not significant (p=0.068). 
 
Subanalysis: Associations between Bone Protective Therapy Use and BMD loss over time in patients who underwent ≥2 
DXA Scans 
 
In total, 91 (59.5%) patients have undergone at least 2 DXA scans, of whom 57 (62.6%) experienced a decreased T-
score from their first and last DXA scan representing a loss in BMD, while 34 (37.4%) did not show BMD loss. 
 
Of the 91 patients who underwent serial DXA scans, 51 (56.0%) were taking BPT and 40 (44.0%) were not. On 
examining the patients taking BPT, 29 (31.9%) patients experienced bone loss over time and 22 (24.2%) did not. Of the 
patients who were not receiving BPT, 28 (30.8%) patients experienced bone loss over time and 12 (13.2%) patients did 
not. However, these differences are not significantly significant (p=0.199). 
 
When looking specifically at bisphosphonate use and BMD loss over time, there was a statistically significant difference 
when looking at individuals who underwent ≥2 DXA scans (Figure 3). Of patients on bisphosphonates, 15 (16.5%) 
experienced BMD loss compared to 17 (18.7%) who did not. Of the patients not on bisphosphonates, 42 (46.2%) 
experienced BMD loss compared to 17 (18.7%) who did not (p=0.022). This indicates that patients not taking 


















The prevention of GIOP with BPT is recommended for patients who are to receive ≥3 months of ≥7.5 mg of 
prednisolone or equivalent per day. BPTs that have shown effectiveness for this indication include calcium plus vitamin 
D, bisphosphonates, denosumab, and teriparatide12. Per current guidelines, approximately 92% of PMR patients 
should be put on GIOP prophylaxis11. 
 
In the literature, adherence to guidelines is varied. Two studies reported approximately 60% of PMR patients received 
osteoporosis prophylaxis13,14, while another reported 48%11. One Japanese cross-sectional study noted that only 23% 
of physicians adhered to the Japanese GIOP prevention guidelines. However, this adherence increased to 57% if the 
GC dose exceeded 7.5 mg of prednisolone per day15.  This is comparable to our study, revealing an adherence rate of 
52%. 
 
Interventions to encourage BPT prescription in patients taking long-term GCs have been attempted16. A Dutch 
randomized control trial investigated whether reminders from pharmacists to physicians prescribing GCs to also 
provide BPT would improve prescription of bisphosphonates. However, pharmacist contact did not significantly 
improve prescription of bisphosphonates after a 6-month follow-up period.  
 
Additionally, it appears that patients who are prescribed BPT may not be receiving adequate protection. This is 
evidenced by the significantly lower T-score in patients who are taking BPT, in addition to 73% of patients having T-
scores consistent with osteopaenia or osteoporosis. However, this observation is limited by the cross-sectional nature 
of this study, where the temporality between BMD loss and use of BPT cannot be concluded. As such, we cannot 
conclude if patients developed BMD loss prior to or after initiating BPT or glucocorticoid use.  
 
The subgroup analysis examining patients who received ≥2 DXA scans show that majority of patients not taking 
bisphosphonates experienced BMD loss over time. A meta-analysis that investigated 9 randomized control trials 
reported that bisphosphonates increased BMD in the lumbar spine, total hip, and trochanter when given for 
prevention of GIOP17.  
 
A limitation in this study pertains to patient compliance. One cross-sectional study conducted in Denmark reported 
that compliance to BPT in PMR patients was 89%18. Unfortunately, BPT compliance could not be determined from our 




Several studies have examined the use of DXA scans in patients taking GCs to monitor for BMD loss. Consistently, it 
appears that, BMD monitoring through DXA scans, are not commonly performed15,19,20. Since our patient group only 
considers patients who underwent a DXA scan, it is possible that the PMR patients in our analysis were limited to 
individuals with ready access to CUH, which calls into question the generalizability of our results. 
 
Additionally, there was no information in the database regarding glucocorticoid dosing or when the glucocorticoid was 
initiated. As such, we cannot determine whether these factors played a role in DXA scan results or correlated with BPT 
use and remains a confounding variable here.  
 
To date, this is the only study that has examined the effectiveness of GC-induced osteoporosis GIOP prevention in 
PMR patients in Ireland. Here, we have demonstrated that there is a gap in the management of PMR patients, which 
exposes an opportunity for improvement in these patients. Future directions should be aimed at reaching out to the 
General Practitioners of individual patients to determine the dosing of GC and when it was initiated, in addition to 
confirming prescription of BPTs and identifying trends in medication compliance.  
 
 
Declaration of Conflicts of Interest: 





University College Cork 
Brookfield Health Sciences Complex, Rm 2.59 







1. Crowson C, Matteson E, Myasoedova E, Michet C, Ernste F, Warrington K et al. The lifetime risk of adult-onset 
rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633-
639. 
2. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United 
Kingdom, 1990–2001. Ann Rheum Dis 2006; 65(8): 1093–1098.   
3. Dejaco C, Singh Y, Perel P, Hutchings A, Camellino D, Mackie S et al. Current evidence for therapeutic interventions 
and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European 
League Against Rheumatism/American College of Rheumatology recommendations for the management of 
polymyalgia rheumatica. Ann Rheum Dis. 2015;74(10):1808-1817.  
4. Ameer F, McNeil J. Polymyalgia rheumatica: clinical update. Australian Family Physician. 2017;43(6):373-376.  
5. Curtis J, Westfall A, Allison J, Bijlsma J, Freeman A, George V et al. Population-based assessment of adverse events 
associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420-426.  
6. McDonough A, Curtis J, Saag K. The epidemiology of glucocorticoid-associated adverse events. Curr Opin 
Rheumatol. 2008;20(2):131-137.  
7. Grossman J, Gordon R, Ranganath V, Deal C, Caplan L, Chen W et al. American College of Rheumatology 2010 
Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res 
(Hoboken). 2010;62(11).   
8. Osteoporosis Guidelines for Health Professionals [Internet]. Dublin: Irish Osteoporosis Society; 2011 [cited 3 
February 2018]. Available from: https://www.icgp-education.ie/osteoporosis/Osteoporosis-Soc-Guidelines-
2011.pdf 
9. Wallach S, Cohen S, Reid D, Hughes R, Hosking D, Laan R et al. Effects of Risedronate Treatment on Bone Density 
and Vertebral Fracture in Patients on Corticosteroid Therapy. Calcif Tissue Int. 2000;67(4):277-285.  
10. Guzman-Clark J, Fang M, Sehl M, Traylor L, Hahn T. Barriers in the management of glucocorticoid-induced 
osteoporosis. Arthritis Rheum. 2007;57(1):140-146.  
 
11. Naranjo A, López R, García-Magallón B, Cáceres L, Francisco F, Jiménez-Palop M et al. Longitudinal practice 
patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica. 
Rheumatology Int. 2014;34(10):1459-1463 
12. van Staa T, Geusens P, Pols H, de Laet C, Leufkens H, Cooper C. A simple score for estimating the long-term risk of 
fracture in patients using oral glucocorticoids. QJM. 2005;98(3):191-198.  
13. Helliwell T, Hider S, Mallen C. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. 
Br J Gen Pract. 2013;63(610):361-366.  
14. Yurdakul FG, Bodur H, Sivas F, Baskan B, Eser F, Yilmaz O. Clinical Features, Treatment and Monitoring in Patients 
with Polymyalgia Rheumatica. Arch Rheumatol. 2015;30(1):28-33.  
15. Kirigaya D, Nakayama T, Ishizaki T, Ikeda S, Satoh T. Management and Treatment of Osteoporosis in Patients 
Receiving Long-term Glucocorticoid Treatment: Current Status of Adherence to Clinical Guidelines and Related 
Factors. Intern Med. 2011;50(22):2793-2800.  
16. Klop C, de Vries F, Vinks T, Kooij M, van Staa T, Bijlsma J et al. Increase in prophylaxis of glucocorticoid-induced 
osteoporosis by pharmacist feedback: a randomised controlled trial. Osteoporosis Int. 2013;25(1):385-392.  
17. Kan S, Yuan Z, Li Y, Ai J, Xu H, Sun J, et al. Alendronate prevents glucocorticoid-induced osteoporosis in patients 
with rheumatic diseases. Medicine (Baltimore). 2016;95(25):e3990.  
18. Emamifar A, Gildberg-Mortensen R, Andreas Just S, Lomborg N, Asmussen Andreasen R, Jensen Hansen I. Level of 
Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant 
Cell Arteritis: A Cross-Sectional Study. Int J Rheumatol. 2015;2015:1-5. 
19. Gera C & VijIJ A. Glucocorticoid-induced osteoporosis: unawareness or negligence in India?. Int J Rheum Dis. 
2009;12(3):230-233.  
20. Sadat-Ali M, Alelq A, Alshafei B, Al-Turki H, Abujubara M. Osteoporosis prophylaxis in patients receiving chronic 
glucocorticoid therapy. Ann Saudi Med. 2009;29(3):215-8. 
